On June 2, 2025, French pharmaceutical giant Sanofi announced its acquisition of U.S.-based Blueprint Medicines for up to $9.5 billion, marking the largest European healthcare deal of the year.
The acquisition of Sanofi Blueprint Medicines will enhance Sanofi’s immunology and rare disease portfolio with Blueprint’s FDA-approved drug Ayvakit, as detailed in a press release on Sanofi’s website, reported by Reuters.
According to Bloomberg, Sanofi will purchase shares of Blueprint for $129 each in cash, reflecting a premium that has increased Blueprint’s stock price in premarket trading. Blueprint specialises in treating systemic mastocytosis, a rare blood disorder, and offers Ayvakit, the only approved therapy for its advanced form. The company also has a promising pipeline that includes elenestinib and BLU-808. CEO Paul Hudson described the acquisition as a “strategic leap” for Sanofi’s focus on immunology.
We announced an agreement to acquire Blueprint Medicines, a biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases.
— Sanofi (@sanofi) June 2, 2025Strategic and Financial Impact
J.P. Morgan analysts project Ayvakit could generate $2 billion annually by 2030, strengthening Sanofi’s rare disease portfolio. The acquisition aligns with Sanofi’s R&D push, following deals for Vigil Neuroscience and Inhibrx, despite a recent lung disease drug trial setback. The move taps U.S. manufacturing incentives, positioning Sanofi as a global immunology leader.
Industry and Public Reactions
The addition of the Ayvakit systemic mastocytosis drug has been hailed as a game changer. Some investors expressed caution over its high valuation, but analysts see long-term growth, according to Livemint. The pharma deal for 2025 underscores Sanofi’s ambition to outpace its competitors.
Sanofi’s acquisition of Blueprint Medicines solidifies the company’s leadership in immunology and therapies for rare diseases, strengthening its competitive position worldwide. As the pharmaceutical landscape evolves in 2025, this deal underscores Sanofi’s strategic shift towards innovation and emphasises its commitment to addressing unmet medical needs.
